---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-099173"
form_type: "8-K"
ticker: "KNSA"
cik: "0001730430"
company_name: "Kiniksa Pharmaceuticals International, plc"
filed_at: "2021-08-03T23:59:59+00:00"
generated_at: "2026-06-29T23:28:06.238077+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kiniksa posts Q2 ARCALYST revenue of $7.7M; net loss $41.6M; guides Q3 rev $9-10M

## Summary
- ARCALYST net revenue $7.7M in first quarter of sales (April 1 launch); >100 physicians prescribed in Q2.
- Net loss $41.6M vs $37.5M YoY; operating expenses $48.3M (incl $5.7M stock comp).
- Cash and investments $225.9M, no debt; expects to fund operations into 2023.
- Q3 2021 ARCALYST revenue guidance $9-10M; pipeline: mavrilimumab Ph3 data Q1 2022, KPL-404 Ph2 start Q4 2021.

## SEC filing metadata
- accession: 0001104659-21-099173
- form_type: 8-K
- ticker: KNSA
- cik: 0001730430
- company_name: Kiniksa Pharmaceuticals International, plc
- filed_at: 2021-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730430/000110465921099173/0001104659-21-099173-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730430/000110465921099173/tm2123663d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-099173
- JSON: https://secwatch.observer/filing/0001104659-21-099173.json
- Plain text: https://secwatch.observer/filing/0001104659-21-099173.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.